Cantor Fitzgerald Reaffirms Overweight Rating for Celldex Therapeutics (NASDAQ:CLDX)

Cantor Fitzgerald reissued their overweight rating on shares of Celldex Therapeutics (NASDAQ:CLDX) in a research note released on Thursday morning,Benzinga reports. Cantor Fitzgerald currently has a $67.00 price target on the biopharmaceutical company’s stock.

CLDX has been the topic of a number of other reports. Wells Fargo & Company upgraded shares of Celldex Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Thursday, September 26th. The Goldman Sachs Group started coverage on shares of Celldex Therapeutics in a research report on Monday, September 30th. They issued a “neutral” rating and a $45.00 target price on the stock. Citigroup started coverage on shares of Celldex Therapeutics in a report on Monday, October 7th. They set a “buy” rating and a $70.00 price target for the company. HC Wainwright reissued a “buy” rating and set a $80.00 price objective on shares of Celldex Therapeutics in a report on Thursday, December 19th. Finally, Wolfe Research cut Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a report on Friday, September 27th. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Celldex Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $62.25.

Celldex Therapeutics Stock Up 4.0 %

Shares of CLDX stock opened at $26.81 on Thursday. The business has a fifty day simple moving average of $26.12 and a 200 day simple moving average of $32.70. The company has a market cap of $1.78 billion, a P/E ratio of -10.43 and a beta of 1.57. Celldex Therapeutics has a twelve month low of $22.93 and a twelve month high of $53.18.

Insider Activity

In other news, CEO Anthony S. Marucci purchased 11,500 shares of the company’s stock in a transaction dated Monday, November 11th. The shares were purchased at an average price of $26.82 per share, for a total transaction of $308,430.00. Following the transaction, the chief executive officer now owns 40,284 shares of the company’s stock, valued at approximately $1,080,416.88. This trade represents a 39.95 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 3.80% of the company’s stock.

Hedge Funds Weigh In On Celldex Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Teachers Retirement System of The State of Kentucky grew its holdings in Celldex Therapeutics by 5.1% during the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 42,628 shares of the biopharmaceutical company’s stock worth $1,449,000 after acquiring an additional 2,070 shares during the period. Geode Capital Management LLC boosted its position in shares of Celldex Therapeutics by 0.4% during the 3rd quarter. Geode Capital Management LLC now owns 1,540,513 shares of the biopharmaceutical company’s stock valued at $52,372,000 after purchasing an additional 6,557 shares in the last quarter. Barclays PLC grew its stake in Celldex Therapeutics by 140.7% during the third quarter. Barclays PLC now owns 130,381 shares of the biopharmaceutical company’s stock worth $4,431,000 after purchasing an additional 76,207 shares during the period. Y Intercept Hong Kong Ltd increased its holdings in Celldex Therapeutics by 11.5% in the third quarter. Y Intercept Hong Kong Ltd now owns 30,538 shares of the biopharmaceutical company’s stock worth $1,038,000 after purchasing an additional 3,146 shares in the last quarter. Finally, XTX Topco Ltd acquired a new position in Celldex Therapeutics in the third quarter valued at approximately $1,561,000.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.